Loading clinical trials...
Loading clinical trials...
This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the potential risk factors for its adverse drug reactions.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Ningming County Hospital of Chinese Medicine
Changzuo, Guangxi, China
Fangchenggang City Hospital of Chinese Medicine
Fangchenggang, Guangxi, China
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, China
Shanglin County Hospital of Chinese Medicine
Nanning, Guangxi, China
Long'an County Hospital of Chinese Medicine
Nanning, Guangxi, China
Luohe Hospital of traditional Chinese Medicine
Luohe, Henan, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Second Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
The First Affiliated Hospital of Henan University of traditional Chinese Medicine
Zhengzhou, Henan, China
Start Date
August 17, 2020
Primary Completion Date
September 1, 2023
Completion Date
December 1, 2023
Last Updated
November 15, 2022
30,000
ESTIMATED participants
Qizhi Tongluo Capsules
DRUG
Lead Sponsor
Zhong Wang
Collaborators
NCT07216846
NCT06723860
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions